72 results about "Plaque area" patented technology

The invention provides a carotid plaque identification method based on cross-modal prediction from CTA to MRA. The method comprises the following steps: a data collection step: paired carotid CTA andMRA image data are collected; plaque segmentation and model training: carotid artery lumens of CTA and MRA are positioned firstly, then carotid artery plaques are segmented, plaque area images of CTAand MRA are obtained, the plaque area images of CTA and MRA are sent to a pix2pix or cycle-GAN network to be trained, and a model obtained after preliminary training is obtained. According to the method, a complete and novel algorithm flow is designed, the carotid artery lumen and plaque on the CTA image are automatically segmented by using an improved deep learning Multiplan-net algorithm, and anoptimized adversarial generative network is designed on the basis to perform CTA data amplification, so that the segmentation precision is further improved.

The invention relates to a meat quality detection system. The system comprises an image acquisition module, an image processing module, a characteristic value extraction module, a spectral analysis module and a data fusion processing module, wherein the image acquisition module is used for acquiring an adipose tissue image of a meat sample; the image processing module is used for extracting a culture medium from the adipose tissue image; the characteristic value extraction module is used for acquiring a ratio of the total area of bacterial plaques in the culture medium to the area of the culture medium; the spectral analysis module is used for analyzing a near infrared spectrum of the sample so as to acquire structure composition data of the meat sample; and the data fusion processing module is used for carrying out fusion processing on the ratio acquired by the characteristic value extraction module and the structure composition data of the meat sample so as to obtain an actual output value. The culture medium is a fixed region which is detected in the adipose tissue image and is only provided with adipose tissues of the meat sample. The actual output value represents the quality of the meat sample. The invention also provides a meat quality detection method. The meat quality detection system and the meat quality detection method can rapidly and accurately detect the meat quality and have the advantages of simple structure and detection process.

The invention relates to the technical field of medicine, and provides new application of macrophage beta-profilin-1, namely application of macrophage beta-profilin-1 to preparation of a drug for preventing or treating atherosclerosis. It is proved through experiments that in comparison with wild type mice, the serum total cholesterol content of macrophage beta-arrestin-1 specificity myelogenous knockout mice is remarkably increased, and it is found through oil red O dyeing that the aorta overall plaque area and the plaque area of aorta roots are obviously increased compared with those of the wild type mice. By changing the macrophage beta-arrestin-1 gene expression level through virus transfection, and it is found that macrophage phagocytosis lipid is increased by interfering beta-arrestin-1 expression and is decreased by overexpressing beta-arrestin-1. The results show that the beta-arrestin-1 gene has a protective effect on the severity degree and prognosis of atherosclerosis.

The invention relates to the field of natural medicines, and particularly relates to use of beta-elemene and derivatives thereof in preventing atherosclerosis, and in particular relates to an application in preparation of medicines for treating atherosclerosis. Test results show that beta-elemene and derivatives can remarkably reduce the atherosclerotic plaque area in the coronary artery of an animal model, and meanwhile has remarkable improving effect on two key links in development process of atherosclerosis: adhesion of leukocyte and endothelial cells and peroxidation of lipids. Expression of adherence factors closely related to atherosclerosis can be reduced, so that peroxidation damage of endothelial cells in vitro and in vivo caused by high fat and H2O2 is avoided.

The invention provides a leaf disease identification method and system. The method includes the following steps that: plaque detection is performed on a blade to be identified, each plaque region on the blade to be identified is obtained, the surface appearance feature words and color feature words of the same position in any plaque region form a word pair; the word pairs are converted into corresponding compound feature words in a compound feature dictionary one by one, and the composite feature histogram of the leaf to be identified is constructed according to the number of times of the appearance of the compound feature words on the blade to be identified; and the compound feature histogram is used as the input of a pre-obtained disease classifier, and the disease of the leaf is identified according to the output result of the disease classifier. With the leaf disease identification method and system of the invention adopted, a blade or disease plaque area is not required to be pre-segmented in an image, instead, the words in the compound feature vocabulary of the image are put into statistics, so that the type of the disease can be identified. The leaf disease identification method and system have the advantages of high recognition rate and high recognition speed.

The invention discloses a traditional Chinese medicine composition improving dementia and a preparation method and application thereof. The traditional Chinese medicine composition improving the dementia is prepared from a rhizoma anemarrhenae extract, a folium ginkgo extract, a rhizoma curcumae longae extract, soybean lecithin, a kirilow rhodiola root extract, a radix polygalae extract, a sharpleaf galangal fruit extract, a green tea extract, a grape seed extract, phosphatidylserine, Y-aminobutyric acid, euphausia superba oil powder and punicosides. The traditional Chinese medicine composition can obviously decrease the beta-AP plaque area inside the brain, forms and number of nerve cells around an injection region and in a more distant region can be obviously improved, and a protective effect on the neuronal toxicity caused by beta-AP is achieved. Meanwhile, according to the experiment, an objective basis is provided for further researching and developing the traditional Chinese medicine for treating the dementia by researching the reaction and action mechanism of a traditional Chinese medicine composition dementia animal model.

The invention relates to a method for evaluating a plaque removing effect on the surface of a space cabin material based on image analysis, which comprises the following steps: firstly, the surface ofthe material before and after the plaque removing is shot by a camera on a plaque removing device respectively to obtain a plaque image before and after the plaque removing; and secondly; the highlight regions in plaque images were accurately obtained and labeled by a clustering method; the plaque image of the marked high-light area is subjected to high-light removing treatment; the feature vector is normalized as the data set of the neural network to train the model, which is used to identify and mark the plaque; the area of plaque region marked by plaque image is calculated; wherein the removal rate is the ratio of the area of labeled plaque in the image before and after plaque removal. As the plaque area in the image before and after the plaque removal can be effectively obtained, theplaque removal efficiency can be accurately obtained.

The invention discloses a function and application of an interferon regulatory factor 9 (IRF9) gene in atherosclerosis (AS), belonging to the field of gene functions and applications. According to the function and application disclosed by the invention, LDLR (Low Density Lipoprotein Receptor)-/- mice and IRF9-/-LDLR-/- mice are taken as experimental subjects, an atherosclerosis model is obtained by high fat induction, and AS model mouse plaque area determination and inclusion analysis are carried out; results show that compared with LDLR-/- mice, the aortal plaque area of the IRF9-/-LDLR-/- mice is significantly increased. The results indicate that the function of IRF9 gene in atherosclerosis is manifested by the action in inhibiting aortal plaque formation, especially inhibiting atherosclerosis. As for the function of the IRF9 gene, IRF9 gene can be used for preparing medicaments for treating atherosclerosis.

The invention discloses a function and application of an MAPK (mitogen-activated protein kinase) signal-integrating kinase 1 (Mnk1) in treatment of the atherosclerosis and belongs to the field of a function and application of a gene. According to the invention, an ApoE<-/-> mouse and an Mnk1<-/->ApoE<-/-> mouse are used as experimental objects and an atherosclerosis module is obtained by high fat diet induction; the result shows that compared with the ApoE<-/-> mouse, the gene defect of the Mnk1 obviously reduces the plaque area of an aorta tree, reinforces stability of an aortic sinus plaque and obviously reduces the inflammatory response. The invention shows that the function of the Mnk1 in the atherosclerosis mainly represents promotion for forming of the aortic plaque and particularly promotion of the atherosclerosis. Aiming at the function of the Mnk1, the Mnk1 can be used as a drug target for screening a medicament for preventing, relieving and/or treating the atherosclerosis and an inhibitor of the Mnk1 can be used for preparing the medicament for preventing, relieving and/or treating the atherosclerosis.

The invention discloses a function and application of an MAPK (mitogen-activated protein kinase) signal-integrating kinase 2 (Mnk2) in treatment of the atherosclerosis and belongs to the field of a function and application of a gene. According to the invention, an ApoE<-/-> mouse and an Mnk2<-/->ApoE<-/-> mouse are used as experimental objects and an atherosclerosis module is obtained by high fat diet induction; the result shows that compared with the ApoE<-/-> mouse, the gene defect of the Mnk2 obviously reduces the plaque area of an aorta, reinforces stability of an aortic sinus plaque and obviously reduces the inflammatory response. The invention shows that the function of the Mnk2 in the atherosclerosis mainly represents promotion for forming of the aortic plaque and particularly promotion for the atherosclerosis. Aiming at the function of the Mnk2, the Mnk2 can be used as a drug target for screening a medicament for preventing, relieving and/or treating the atherosclerosis and an inhibitor of the Mnk2 can be used for preparing the medicament for preventing, relieving and/or treating the atherosclerosis.

The invention relates to an application of a Tibetan medicine namely epipremnum aureum flower in preparation of a medicine for treating atherosclerosis, and belongs to the technical field of traditional Chinese medicine. The invention shows that at the animal level, the epipremnum aureum flower alcohol extract can significantly reduce the atherosclerotic plaque area of mice, and the specific mechanism is shown as follows: on one hand, cholesterol absorption is inhibited by reducing the SR-BI expression level, and on the other hand, cholesterol metabolism is promoted to generate bile acid by increasing the CYP7A1 gene expression; and at the cellular level, the epipremnum aureum flower alcohol extract can significantly reduce cholesterol uptake of cells and reduce expression of a macrophagemarker CD36 to reduce cholesterol uptake of macrophages so as to reduce macrophage foaming. The invention provides scientific data and an idea basis for clinical treatment of atherosclerosis through the epipremnum aureum flower, and provides data support for a new method and an action target for clinically preventing and treating cardiovascular diseases.

The invention discloses a calcified plaque detection decision system based on an artificial intelligence algorithm. According to the system, an intravascular image is acquired based on an intravascular image or an intravascular radiography and intravascular image integrated system or an intravascular imaging-calcified plaque decision integrated system; if the intravascular image is an integrated image of OCT and IVUS, the OCT image and the IVUS image are collected at the same time, and the positions of the OCT image and the IVUS image in rotation and pull-back are consistent, wherein alignmentis conducted through an image processing algorithm; the collected OCT image and IVUS image are automatically detected and segmented to obtain a calcified plaque area; the related characteristics of the calcified plaque are detected and quantified; the related characteristics are displayed on a display terminal after two-dimensional and three-dimensional rendering; the calcified plaques are classified and decided, and an optimal decision scheme is automatically recommended; and a result after calcified plaque operation is evaluated, and stent intervention is performed after optimizing. According to the invention, automatic identification and segmentation quantification of calcified plaques in intravascular image detection are realized, and accurate data support is provided for doctors.

The invention belongs to the field of medicines, and relates to a novel fusion protein. The fusion protein is combined with CD47 molecules on the surfaces of deposited cells in atherosclerotic plaquesto block the transmission of signals to macrophages, relieve the inhibition of a phagocytic function of macrophages, promote the macrophages to phagocytize the deposited cells in the atheroscleroticplaques, and delay and reverse the progress of the atherosclerosis course. Animal experiments of atherosclerosis early-stage and middle-late-stage model mice prove that after the fusion protein is injected, the aorta total length, the aorta root and the plaque area at the aortic arch of an experimental mouse are remarkably reduced. The fusion protein can be used for delaying and reversing the progress of the disease course of an atherosclerosis model animal and reducing related acute cardiovascular events of the atherosclerosis model animal, and further can be used for preparing a new medicinefor clinically treating atherosclerosis.

The invention discloses function and application of signal regulatory protein 1 (SHPS1) treating atherosclerosis, and belongs to the field of functions and application of genes. According to the technical scheme, an ApoE<-/-> mouse and a SHPS1<-/->ApoE<-/-> mouse are taken as experiment objects, atherosclerotic models are obtained through high-fat diet induction, and results show that compared with the ApoE<-/-> mouse, SHPS1 gene defect leads to substantial reduction of the aorta plaque area, stability enhancement of aortic sinus plaque and mitigation of inflammation reaction. The results show that SHPS1 mainly has the effects of promoting formation of aorta plaque area and especially promoting atherosclerosis in the functions of atherosclerosis. Aiming at the above functions of SHPS1, SHPS1 can be used as a medicine target and is applied to screen medicines for preventing, alleviating and/or treating atherosclerosis, and an inhibitor of SHPS1 is applicable to prepare medicines for preventing, alleviating and/or treating atherosclerosis.

The invention discloses applications of an interferon regulatory factor 1 gene in treatment of atherosclerosis, belonging to the field of the functions and applications of a gene. An atherosclerosis model is obtained by taking ApoE-/-mice and IRF1-/-ApoE-/-mice as experimental objects through induction of high-fat diet, results show that the IRF1 gene defects markedly reduce the plaque area of the aorta, enhance the stability of aortic sinus plaque, and markedly lighten the inflammatory response compared with the ApoE-/-mice. The function of the IRF1 in the atherosclerosis is mainly reflected by the fact that the IRF1 achieves the effect of promoting the formation of the aortic plaque, especially the effect of promoting the atherosclerosis. Aiming to the functions of the IRF1, the IRF1 can be used as a drug target for screening drugs preventing, alleviating and/or treating atherosclerosis, and an inhibitor of the IRF1 can be used for preparing a drug for preventing, alleviating and/or treating atherosclerosis.

The invention discloses a method for treating diabetes and atherosclerosis. The method comprises the following steps of 1, preparing umbilical cord blood stem cells; 2, exciting autologous peripheralblood stem cells; 3, injecting umbilical cord blood cell factors to blood, and combining the umbilical cord blood stem cells and the autologous peripheral blood stem cells for treatment; 4, periodically paying follow-up visits to curers for artery atherosclerotic plaque area, blood glucose and triglyceride changes. Due to combination of the umbilical cord blood stem cells and the autologous peripheral blood stem cells for treatment, the artery atherosclerotic plaque is decreased which shows that treatment is effective; the recent effect for treating the diabetes is obvious, however, the lasting time is short, and the treatment effect needs to be consolidated and improved; the blood lipid level of the high lipid patient can be rapidly and obviously lowered, the lasting time is longer, and the treatment effect for patients is obvious; due to combination of the umbilical cord blood stem cells and the autologous peripheral blood stem cells for treatment of diabetes and atherosclerosis, theeffect of treating diabetes and atherosclerosis is better than that of other national and international products, and no side effect is caused.

The invention relates to the technical field of food nutrition, in particular to application of sea cucumber sterol sulfate in an anti-atherosclerosis product. The sea cucumber sterol sulfate is extracted and separated from sea cucumbers and subjected to microencapsulation, and experiments verify that the sea cucumber sterol sulfate and a microcapsule thereof have improvement functions on atherosclerosis. The sterol sulfate is prepared with the sea cucumbers as a raw material, experiments prove that the sea cucumber sterol sulfate can effectively reduce plaque areas of the atherosclerosis, that is, the sea cucumber sterol sulfate can remarkably inhibit the development of the atherosclerosis, indicating that the sea cucumber sterol sulfate can effectively prevent, improve or treat the atherosclerosis.

The invention discloses a pharmaceutical application of composition for treating atherosclerosis, and particularly relates to application of a composition comprising microvesicles and copper ions in preparation of a drug for treating the atherosclerosis. When the composition comprising the microvesicles and copper ions is used for treating the atherosclerosis, the plaque area is significantly reduced while plaque breakage and falling are not caused.